Molecular Diagnostics News and Research

RSS

Great Basin Scientific seeks FDA approval for Group B Strep assay

Great Basin Scientific, Inc., a molecular diagnostics company, today announced it has submitted its Group B Strep assay to the U.S. Food and Drug Administration for 510(k) clearance.

19 Nov 2014

EKF Molecular Diagnostics to present at AMP annual meeting

EKF, announces that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology.

From EKF Diagnostics 6 Nov 2014

VTT develops innovative magnetometer for applications such as medical imaging

VTT Technical Research Centre of Finland has developed an innovative magnetometer that can replace conventional technology in applications such as neuroimaging, mineral exploration and molecular diagnostics. Its manufacturing costs are between 70 and 80 per cent lower than those of traditional technology, and the device is not as sensitive to external magnetic fields as its predecessors. The design of the magnetometer also makes it easier to integrate into measuring systems.

6 Nov 2014

UCLA research could lead to simple saliva test for early diagnosis of deadly diseases

UCLA research could lead to a simple saliva test capable of diagnosing — at an early stage — diabetes and cancer, and perhaps neurological disorders and autoimmune diseases.

30 Oct 2014

Molecular diagnostics and blood screening systems: an interview with Dr Bos and Dr Koppelman

Screening blood donations and molecular diagnostics for patients started in the nineties. At the beginning, the level of automation in molecular diagnostic testing was limited; most of the work had to be done manually.

12 Oct 2014

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals.

10 Oct 2014

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients.

30 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

AIT, BioVendor and SCIENION partner to develop in-vitro diagnostic test for colon cancer

The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.

24 Sep 2014

Understanding ways to treat, cure eosinophilic gastritis

Investigators at Cincinnati Children's Hospital Medical Center have published the first study to extensively characterize eosinophilic gastritis (EG).

24 Sep 2014

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.

From EKF Diagnostics 23 Sep 2014

Two fully automated molecular testing systems for blood and plasma donor screening launched by Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening, in markets accepting the CE mark. The cobas 6800/8800 Systems offer the fastest time to results with the highest throughput available, along with the longest walk-away time, enabling laboratory staff to drive increased workflow efficiencies, while adapting to their ever-changing testing demands.

From Roche Sequencing and Life Science 2 Sep 2014

Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus.

20 Aug 2014

BGRF scientists propose Oncofinder method for accurate analysis of gene expression data

Scientists from the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, propose a new concept for signalome-wide analysis of changes in intracellular pathways, called OncoFinder, which allows for accurate and robust cross-platform analysis of gene expression data.

19 Aug 2014

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose.

14 Aug 2014

Roka Bioscience reports increased revenue of $1.4M with 107% year-over-year growth

Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today reported its financial results for the three and six months ended June 30, 2014.

11 Aug 2014

AMP publishes updated position statement on the regulation of LDPs

The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular testing professionals and leading education initiatives, discussions, and policy actions central to improving the development and application of molecular diagnostics, today reaffirmed its position that the vast majority of laboratory developed tests (LDTs), or laboratory developed procedures (LDPs)—a term coined by AMP to more appropriately capture the nature of these processes as medical services—should continue operating under the regulation of the Clinical Laboratory Improvement Amendments program at the Centers for Medicare & Medicaid Services, and not be subject to pre-market review by the U.S. Food and Drug Administration, as suggested in the draft guidance notification issued to Congress on July 31, 2014.

4 Aug 2014

New molecular test kit predicts survival outcomes in kidney cancer patients

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test kit that can predict treatment and survival outcomes in kidney cancer patients. This breakthrough was recently reported in European Urology, the world's top urology journal.